Skip to main content
Top
Published in: Journal of Clinical Immunology 1/2013

01-01-2013 | Original Research

EVER2 Deficiency is Associated with Mild T-cell Abnormalities

Authors: Amandine Crequer, Capucine Picard, Vincent Pedergnana, Annick Lim, Shen-Ying Zhang, Laurent Abel, Slawomir Majewski, Jean-Laurent Casanova, Stefania Jablonska, Gerard Orth, Emmanuelle Jouanguy

Published in: Journal of Clinical Immunology | Issue 1/2013

Login to get access

Abstract

Epidermodysplasia verruciformis (EV) is a rare genodermatosis characterized by persistent flat warts or pityriasis versicolor-like lesions caused by betapapillomaviruses (EV-HPVs). Autosomal recessive EVER1 and EVER2 deficiencies account for EV in most patients. The mechanisms by which mutations in these partners of the Zinc transporter ZnT1 impair host defense against EV-HPVs are still poorly understood. Keratinocytes of EVER-deficient patients display an alteration of zinc homeostasis and an enhanced proliferative activity. Since EVER proteins are highly expressed in T lymphocytes, we aimed to assess the impact of EVER2 deficiency on T-cell development and function. We studied circulating lymphocyte populations in three adult EV patients sharing the same EVER2 mutation (T150fsX3). We found a normal count of CD4+ and CD8+ T cells and a normal proliferative capacity in response to anti-CD3 stimulation. However, we observed a significant increase of memory CD4+ and effector memory CD8+ T cells, a bias of the TCR Vαβ and Vγδ repertoires and an increase of skin-homing CD4+ T-cell subsets. Our findings suggest that EVER2-deficient patients display mild T-cell abnormalities. It remains unclear whether these abnormalities result from EVER deficiency, chronic EV-HPV infection, or both.
Appendix
Available only for authorised users
Literature
1.
go back to reference Orth G. Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol. 2008;321:59–83.PubMedCrossRef Orth G. Host defenses against human papillomaviruses: lessons from epidermodysplasia verruciformis. Curr Top Microbiol Immunol. 2008;321:59–83.PubMedCrossRef
2.
go back to reference Lutzner MA. Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. Bull Cancer. 1978;65(2):169–82.PubMed Lutzner MA. Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. Bull Cancer. 1978;65(2):169–82.PubMed
3.
go back to reference Orth G. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. Semin Immunol. 2006;18(6):362–74.PubMedCrossRef Orth G. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. Semin Immunol. 2006;18(6):362–74.PubMedCrossRef
4.
go back to reference Prawer SE, Pass F, Vance JC, Greenberg LJ, Yunis EJ, Zelickson AS. Depressed immune function in epidermodysplasia verruciformis. Arch Dermatol. 1977;113(4):495–9.PubMedCrossRef Prawer SE, Pass F, Vance JC, Greenberg LJ, Yunis EJ, Zelickson AS. Depressed immune function in epidermodysplasia verruciformis. Arch Dermatol. 1977;113(4):495–9.PubMedCrossRef
5.
go back to reference Glinski W, Jablonska S, Langner A, Obalek S, Haftek M, Proniewska M. Cell-mediated immunity in epidermodysplasia verruciformis. Dermatologica. 1976;153(4):218–27.PubMedCrossRef Glinski W, Jablonska S, Langner A, Obalek S, Haftek M, Proniewska M. Cell-mediated immunity in epidermodysplasia verruciformis. Dermatologica. 1976;153(4):218–27.PubMedCrossRef
6.
go back to reference Glinski W, Obalek S, Jablonska S, Orth G. T cell defect in patients with epidermodysplasia verruciformis due to human papillomavirus type 3 and 5. Dermatologica. 1981;162(3):141–7.PubMedCrossRef Glinski W, Obalek S, Jablonska S, Orth G. T cell defect in patients with epidermodysplasia verruciformis due to human papillomavirus type 3 and 5. Dermatologica. 1981;162(3):141–7.PubMedCrossRef
7.
go back to reference Majewski S, Skopinska-Rozewska E, Jablonska S, Wasik M, Misiewicz J, Orth G. Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. J Am Acad Dermatol. 1986;15(5 Pt 1):966–73.PubMedCrossRef Majewski S, Skopinska-Rozewska E, Jablonska S, Wasik M, Misiewicz J, Orth G. Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. J Am Acad Dermatol. 1986;15(5 Pt 1):966–73.PubMedCrossRef
8.
go back to reference Pereira de Oliveira WR, Carrasco S, Neto CF, Rady P, Tyring SK. Nonspecific cell-mediated immunity in patients with epidermodysplasia verruciformis. J Dermatol. 2003;30(3):203–9.PubMed Pereira de Oliveira WR, Carrasco S, Neto CF, Rady P, Tyring SK. Nonspecific cell-mediated immunity in patients with epidermodysplasia verruciformis. J Dermatol. 2003;30(3):203–9.PubMed
9.
go back to reference Majewski S, Malejczyk J, Jablonska S, Misiewicz J, Rudnicka L, Obalek S, et al. Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis. J Am Acad Dermatol. 1990;22(3):423–7.PubMedCrossRef Majewski S, Malejczyk J, Jablonska S, Misiewicz J, Rudnicka L, Obalek S, et al. Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis. J Am Acad Dermatol. 1990;22(3):423–7.PubMedCrossRef
10.
go back to reference Kaminski M, Pawinska M, Jablonska S, Szmurlo A, Majewski S, Orth G. Increased natural killer cell activity in patients with epidermodysplasia verruciformis. Arch Dermatol. 1985;121(1):84–6.PubMedCrossRef Kaminski M, Pawinska M, Jablonska S, Szmurlo A, Majewski S, Orth G. Increased natural killer cell activity in patients with epidermodysplasia verruciformis. Arch Dermatol. 1985;121(1):84–6.PubMedCrossRef
11.
go back to reference Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet. 2002;32(4):579–81.PubMedCrossRef Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet. 2002;32(4):579–81.PubMedCrossRef
12.
go back to reference Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. Science. 2007;317(5838):617–9.PubMedCrossRef Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. Science. 2007;317(5838):617–9.PubMedCrossRef
13.
go back to reference Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, Casanova JL. Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? Ann N Y Acad Sci. 2010;1214:18–33.PubMedCrossRef Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, Casanova JL. Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? Ann N Y Acad Sci. 2010;1214:18–33.PubMedCrossRef
14.
go back to reference Lazarczyk M, Pons C, Mendoza JA, Cassonnet P, Jacob Y, Favre M. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med. 2008;205(1):35–42.PubMedCrossRef Lazarczyk M, Pons C, Mendoza JA, Cassonnet P, Jacob Y, Favre M. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med. 2008;205(1):35–42.PubMedCrossRef
15.
go back to reference Landini MM, Zavattaro E, Borgogna C, Azzimonti B, De Andrea M, Colombo E, et al. Lack of EVER2 protein in two epidermodysplasia verruciformis patients with skin cancer presenting previously unreported homozygous genetic deletions in the EVER2 gene. J Invest Dermatol. 2012;132(4):1305–8.PubMedCrossRef Landini MM, Zavattaro E, Borgogna C, Azzimonti B, De Andrea M, Colombo E, et al. Lack of EVER2 protein in two epidermodysplasia verruciformis patients with skin cancer presenting previously unreported homozygous genetic deletions in the EVER2 gene. J Invest Dermatol. 2012;132(4):1305–8.PubMedCrossRef
16.
go back to reference Keresztes G, Mutai H, Heller S. TMC and EVER genes belong to a larger novel family, the TMC gene family encoding transmembrane proteins. BMC Genomics. 2003;4(1):24.PubMedCrossRef Keresztes G, Mutai H, Heller S. TMC and EVER genes belong to a larger novel family, the TMC gene family encoding transmembrane proteins. BMC Genomics. 2003;4(1):24.PubMedCrossRef
17.
go back to reference Haase H, Rink L. Functional significance of zinc-related signaling pathways in immune cells. Annu Rev Nutr. 2009;29:133–52.PubMedCrossRef Haase H, Rink L. Functional significance of zinc-related signaling pathways in immune cells. Annu Rev Nutr. 2009;29:133–52.PubMedCrossRef
18.
go back to reference Yu M, Lee WW, Tomar D, Pryshchep S, Czesnikiewicz-Guzik M, Lamar DL, et al. Regulation of T cell receptor signaling by activation-induced zinc influx. J Exp Med. 2011;208(4):775–85.PubMedCrossRef Yu M, Lee WW, Tomar D, Pryshchep S, Czesnikiewicz-Guzik M, Lamar DL, et al. Regulation of T cell receptor signaling by activation-induced zinc influx. J Exp Med. 2011;208(4):775–85.PubMedCrossRef
19.
go back to reference Lazarczyk M, Dalard C, Hayder M, Dupre L, Pignolet B, Majewski S, et al. EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation. PLoS One. 2012;7(6):e39995.PubMedCrossRef Lazarczyk M, Dalard C, Hayder M, Dupre L, Pignolet B, Majewski S, et al. EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation. PLoS One. 2012;7(6):e39995.PubMedCrossRef
20.
go back to reference Crequer A, Troeger A, Patin E, Ma CS, Picard C, Pedergnagna V, et al. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest. 2012;In press. Crequer A, Troeger A, Patin E, Ma CS, Picard C, Pedergnagna V, et al. Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest. 2012;In press.
21.
go back to reference Crequer A, Picard C, Patin E, D'Amico A, Abhyankar A, Munzer M, Debre M, de Saint-Basile G, Fischer A, Abel L, Orth G, Casanova J.-L., Jouanguy E. Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. In revision Plos one. 2012;In press. Crequer A, Picard C, Patin E, D'Amico A, Abhyankar A, Munzer M, Debre M, de Saint-Basile G, Fischer A, Abel L, Orth G, Casanova J.-L., Jouanguy E. Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. In revision Plos one. 2012;In press.
22.
go back to reference Jablonska S, Dabrowski J, Jakubowicz K. Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res. 1972;32(3):583–9.PubMed Jablonska S, Dabrowski J, Jakubowicz K. Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res. 1972;32(3):583–9.PubMed
23.
go back to reference Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, et al. The vast majority of CLA + T cells are resident in normal skin. J Immunol. 2006;176(7):4431–9.PubMed Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, Dowgiert RK, et al. The vast majority of CLA + T cells are resident in normal skin. J Immunol. 2006;176(7):4431–9.PubMed
24.
go back to reference Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9(10):679–91.PubMed Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol. 2009;9(10):679–91.PubMed
25.
go back to reference Pauls K, Schon M, Kubitza RC, Homey B, Wiesenborn A, Lehmann P, et al. Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J Invest Dermatol. 2001;117(3):569–75.PubMedCrossRef Pauls K, Schon M, Kubitza RC, Homey B, Wiesenborn A, Lehmann P, et al. Role of integrin alphaE(CD103)beta7 for tissue-specific epidermal localization of CD8+ T lymphocytes. J Invest Dermatol. 2001;117(3):569–75.PubMedCrossRef
26.
go back to reference Aochi S, Nakanishi G, Suzuki N, Setsu N, Suzuki D, Aya K, et al. A novel homozygous mutation of the EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. Br J Dermatol. 2007;157(6):1265–6.PubMedCrossRef Aochi S, Nakanishi G, Suzuki N, Setsu N, Suzuki D, Aya K, et al. A novel homozygous mutation of the EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. Br J Dermatol. 2007;157(6):1265–6.PubMedCrossRef
27.
go back to reference Nehme NT, Pachlopnik Schmid J, Debeurme F, Andre-Schmutz I, Lim A, Nitschke P, et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T cells survival. Blood. 2011. Nehme NT, Pachlopnik Schmid J, Debeurme F, Andre-Schmutz I, Lim A, Nitschke P, et al. MST1 mutations in autosomal recessive primary immunodeficiency characterized by defective naive T cells survival. Blood. 2011.
28.
go back to reference Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schaffer AA, et al. The phenotype of human STK4 deficiency. Blood. 2012. Abdollahpour H, Appaswamy G, Kotlarz D, Diestelhorst J, Beier R, Schaffer AA, et al. The phenotype of human STK4 deficiency. Blood. 2012.
30.
go back to reference Randall KL, Chan SS, Ma CS, Fung I, Mei Y, Yabas M, et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med. 2011;208(11):2305–20.PubMedCrossRef Randall KL, Chan SS, Ma CS, Fung I, Mei Y, Yabas M, et al. DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. J Exp Med. 2011;208(11):2305–20.PubMedCrossRef
31.
go back to reference Soler D, Humphreys TL, Spinola SM, Campbell JJ. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood. 2003;101(5):1677–82.PubMedCrossRef Soler D, Humphreys TL, Spinola SM, Campbell JJ. CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood. 2003;101(5):1677–82.PubMedCrossRef
Metadata
Title
EVER2 Deficiency is Associated with Mild T-cell Abnormalities
Authors
Amandine Crequer
Capucine Picard
Vincent Pedergnana
Annick Lim
Shen-Ying Zhang
Laurent Abel
Slawomir Majewski
Jean-Laurent Casanova
Stefania Jablonska
Gerard Orth
Emmanuelle Jouanguy
Publication date
01-01-2013
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 1/2013
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-012-9749-1

Other articles of this Issue 1/2013

Journal of Clinical Immunology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine